CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...